MedTrace Logo

A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)

NCT00189813 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 691

Last updated 2014-08-28

No results posted yet for this study

Summary

This study will examine the efficacy, safety and tolerability of different oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.

Conditions

  • Irritable Bowel Syndrome

Interventions

DRUG

YM060

Sponsors & Collaborators

  • Astellas Pharma Europe B.V.

    collaborator INDUSTRY

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • F. Verbeeck · Director of Late Phase Development

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2005-12-31
Completion
2005-12-31

Countries

  • Bulgaria
  • Czechia
  • Estonia
  • Germany
  • Lithuania
  • Poland
  • Russia
  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00189813 on ClinicalTrials.gov